Cohort study of idiopathic retroperitoneal fibrosis in China
A Prospective Cohort Study of Idiopathic Retroperitoneal Fibrosis in China
This study looks at how idiopathic retroperitoneal fibrosis affects patients in China and how they respond to different treatments.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | Peking Union Medical College Hospital Academic / other |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Trial ID | NCT04312854 on ClinicalTrials.gov |
What this trial studies
This cohort study aims to investigate the disease course and treatment response of patients with idiopathic retroperitoneal fibrosis (IRPF) across China. Patients diagnosed with definite or possible IRPF will be enrolled, and an online database will be established to collect clinical manifestations, demographic features, laboratory characteristics, immunological tests, imaging, and pathological features. The study will focus on understanding the complex clinical phenotype of IRPF and its association with other autoimmune conditions. The primary endpoint is to document the clinical manifestations of IRPF patients, while secondary endpoints will explore various characteristics and treatment outcomes.
Who should consider this trial
Good fit: Ideal candidates are males and females aged 18-75 diagnosed with definite or possible idiopathic retroperitoneal fibrosis.
Not a fit: Patients with malignancies, other autoimmune diseases, or secondary forms of retroperitoneal fibrosis will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of IRPF and improve treatment strategies for affected patients.
How similar studies have performed: While there may be limited studies on IRPF, this cohort approach is novel in the context of a comprehensive registry in China.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Males and females; 18-75 years old with informed consent; Patients diagnosed with definite or possible IRPF. Exclusion Criteria: Secondary forms of IRPF; Pregnant or Females planning to bear a child recently ; Concurrent severe and/or uncontrolled and/or unstable diseases; Patients with malignancy.
Where this trial is running
Beijing, Beijing Municipality
- Peking Union Medical College Hospital — Beijing, Beijing Municipality, China (Recruiting)
Study contacts
- Principal investigator: Wen Zhang, MD — Department of Rheumatology,Peking Union Medical College Hospital
- Study coordinator: Yunyun Fei, MD
- Email: feiyunyun2013@hotmail.com
- Phone: 86-10-69158797
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.